7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days

7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days

7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days

7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days

COVID-19

SnPP Protoporphyrin plus Sunlight exposure

SnPP Protoporphyrin and Sunlight exposure

Sulfonatoporphyrin(TPPS) plus Sunlight exposure.

placebo

Kafr El-sheikh University

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

Efficacy of Based MRI Contrast Media Against Covid-19

Proportion of lung injury score decreased or increased after treatment

Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

Mahmoud Ramadan mohamed Elkazzaz

Principal Investigator

Kafrelsheikh University

Patients and method :
This study will performed on 56 participants tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection and 56 participants will divided into 8 equal groups

Patients
This study will performed on 56 participants tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection and 56 participants will divided into 8 equal groups

intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.
Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection.

Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.

Morbid Obesity

Bariatric Surgery Candidate

Lidocaine

isotonic saline

University Hospital of Caen

Intravenous Lidocaine in Bariatric Surgery.

Effect of Continuous Intravenous Lidocaine on Early Rehabilitation in Bariatric Surgery. A Randomized Double Blind Controlled Study

total postoperative (until day 3) oxycodone consumption (mg)

lidocaine plasma concentration measured at the end of infusion

recovery (in days) which enable discharge from hospital

postoperative pain intensity (visual analogue scale)

proportion of patients with and without postoperative nausea and vomiting

duration (in days) of postoperative intestinal palsy

University Hospital, Caen

Acute Intermittent Porphyria

Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.

rAAV2/5-PBGD vector dosage 1

rAAV2/5-PBGD vector dosage 2

rAAV2/5-PBGD vector dosage 3

rAAV2/5-PBGD vector dosage 4

Clinica Universidad de Navarra

12 Octubre Hospital

Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

Phase I, Multicentre, Open Label, Single Dose, Dose-ranging Clinical Trial to Investigate the Safety and Tolerability of a Gene Therapy rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

To assess the safety and determine the maximum therapeutic safe dose of the investigational gene therapy (GT) product rAAV2/5-PBGD for the treatment of AIP, registering and evaluating the occurrence of Adverse Events and/or Serious Adverse Events at the dose identified will be performed

The information regarding the requirement of specific treatments for symptoms control (analgesics, hemin and glucose endovenous solutions) will be collected.

Anxiety and depression will be assessed by using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) rating scales.

Health-related quality of life will be assessed through the SF-36v2 questionnaire

Digna Biotech S.L.

Porphyria Centre Sweden

University of Navarra

UniQure N.V.

Nationales Centrum für Tumorerkrankungen

Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).

Observational Study of Acute Intermittent Porphyria Patients

The primary objective of this study is to observe the changes of PBG and ALA urinary levels in acute intermittent porphyria patients. The patient will collect an early morning single urine sample protected from light, for the determination of PBG and ALA during each of the study visits (inclusion, follow-up and final visits). If hemin or glucose treatments were necessary, the patient should collect a urine sample before treatment administration, and sent it or carry it to the local investigation center.

The information regarding the need and frequency of hospitalizations will be collected.

The presence and level of anxiety and depression will be assessed by using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) rating scales.

Health-related quality of life will be assessed through the SF-36v2 questionnaire.

The frequency of gastrointestinal, neurological, cardiovascular symptoms, abdominal pain and osteo-muscular pain, any other symptoms that may be considered associated with AIP will be collected.

The information regarding the need and frequency of specific treatments for symptoms control (analgesics, hemin and glucose endovenous solution), will be collected.

Serum samples obtained from the patients at the selection and final visit will be analyzed to determine the presence of total and neutralizing antibodies against AAV5. The presence of antibodies against the PBGD protein will also be identified.

Serum samples will be collected in order to identify potential biological markers related to acute intermittent porphyria

porphyrias/seizures

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

Intravenous Lidocaine in Bariatric Surgery.

Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

Observational Study of Acute Intermittent Porphyria Patients

Najkompletnejšia databáza liečivých bylín podporovaná vedou